Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01338675
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Daehangno, Jongno-gu, Korea, Republic of
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 40
- Registration Number
- NCT01306019
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT01279616
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT01274195
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Daehangno, Jongno-gu, Korea, Republic of
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 16
- Registration Number
- NCT01247701
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT01237951
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 22
- Registration Number
- NCT01203020
- Locations
- 🇺🇸
West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT01200329
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2010-08-09
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT01177371
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
- Conditions
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: Etoposide PhosphateRadiation: External Beam Radiation TherapyProcedure: In Vitro-Treated Peripheral Blood Stem Cell TransplantationRadiation: Intensity-Modulated Radiation TherapyRadiation: Iobenguane I-131Drug: IsotretinoinOther: Laboratory Biomarker AnalysisDrug: MelphalanOther: Pharmacological StudyOther: Questionnaire AdministrationProcedure: Therapeutic Conventional SurgeryDrug: Topotecan HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 99
- Registration Number
- NCT01175356
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.